A Novel Blockade CD47 Antibody With Therapeutic Potential for Cancer

Fangzhen Lin,Mengshang Xiong,Wei Hao,Yuewen Song,Ruoqi Liu,Yuanyuan Yang,Xiangfei Yuan,Dongmei Fan,Yizi Zhang,Mu Hao,Zhou Ye,Yang Lu,Yanjun Zhang,Jianxiang Wang,Dongsheng Xiong

DOI: https://doi.org/10.3389/fonc.2020.615534

IF: 4.7

2021-01-05

Frontiers in Oncology

Abstract:Macrophages as components of the innate immune system play a critical role in antitumor responses. Strategies for targeting CD47 are becoming a hot spot for cancer therapy. The expression of CD47 is exercised by macrophages to make a distinction between “self” or “nonself.” Anti-CD47 antibodies block the interaction between macrophage signal regulatory protein-α (SIRPα) and tumor surface CD47. In this study, we report and assess a novel anti-CD47 blocking antibody named 2C8, which exhibits high affinity and tremendous anticancer effects. More concretely, 2C8 significantly induces macrophages, including protumorigenic subtype M2 macrophages killing tumor cells in vitro , and is revealed to be more effective than commercially available anti-CD47 mAb B6H12.2. In vivo, 2C8 controls tumor growth and extends survival of xenograft mice. The antitumor ability of 2C8 might be applicable to many other cancers. The generation of a novel CD47 antibody contributes to consolidating clinical interest in targeting macrophages for the treatment of malignancy and, moreover, as a supplement therapy when patients are resistant or refractory to other checkpoint therapies or relapse after such treatments.

oncology